Van Welzen, Berend J.; Smit, Colette; Boyd, Anders; Lieveld, Faydra I.; Mudrikova, Tania; Reiss, Peter; Brouwer, Annemarie E.; Hoepelman, Andy I. M.; Arends, Joop E. published the artcile< Decreased all-cause and liver-related mortality risk in HIV/hepatitis B virus coinfection coinciding with the introduction of tenofovir-containing combination antiretroviral therapy>, Synthetic Route of 112-63-0, the main research area is tenofovir antiretroviral therapy human immunodeficiency virus Hepatitis B; HIV; coinfection; hepatitis B virus; liver-related mortality; tenofovir.
Background:The development of efficacious combination antiretroviral therapy (cART) has led to a dramatic decrease in mortality in HIV-pos. patients. Specific data on the impact in HIV/hepatitis B virus (HBV)-coinfected patients are lacking. Methods:In this study, all-cause and cause-specific mortality risks stratified per era of diagnosis are investigated. Data were analyzed from HIV/HBV-coinfected patients enrolled in the ATHENA cohort between Jan. 1, 1998, and Dec. 31, 2017. Risk for (cause-specific) mortality was calculated using Cox proportional hazard regression anal., comparing patients diagnosed before 2003 with those diagnosed ≥2003. Risk factors for all-cause and liver-related mortality were also assessed using Cox proportional hazard regression anal. Results:A total of 1301 HIV/HBV-coinfected patients were included (14 882 person-years of follow-up). One-hundred ninetyeight patients (15%) died during follow-up. The adjusted hazard ratio (aHR) for all-cause mortality in patients diagnosed in or after 2003 was 0.50 (95% CI, 0.35-0.72) relative to patients diagnosed before 2003. Similar risk reduction was observed for liver-related (aHR, 0.29; 95% CI, 0.11-0.75) and AIDS-related mortality (aHR, 0.44; 95% CI, 0.22-0.87). Use of a tenofovir-containing regimen was independently associated with a reduced risk of all-cause and liver-related mortality. Prior exposure to didanosine/stavudine was strongly associated with liver-related mortality. Ten percent of the population used only lamivudine as treatment for HBV. Conclusions:All-cause, liver-related, and AIDS-related mortality risk in HIV/HBV-coinfected patients has markedly decreased over the years, coinciding with the introduction of tenofovir. Tenofovir-containing regimens, in absence of major contraindications, should be strongly encouraged in this population.
Open Forum Infectious Diseases published new progress about AIDS (disease). 112-63-0 belongs to class esters-buliding-blocks, and the molecular formula is C19H34O2, Synthetic Route of 112-63-0.
Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics